Published in J Infect Dis on October 16, 2013
Gut microbiota elicits a protective immune response against malaria transmission. Cell (2014) 2.48
Basigin is a druggable target for host-oriented antimalarial interventions. J Exp Med (2015) 1.48
Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. Nature (2014) 1.29
A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys. Cell Host Microbe (2015) 1.25
Plasmodium falciparum erythrocyte invasion: combining function with immune evasion. PLoS Pathog (2014) 1.17
Estimation of recent and long-term malaria transmission in a population by antibody testing to multiple Plasmodium falciparum antigens. J Infect Dis (2014) 1.07
Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria. FEMS Microbiol Rev (2016) 1.02
A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein. Malar J (2014) 1.00
Crystal structure of PfRh5, an essential P. falciparum ligand for invasion of human erythrocytes. Elife (2014) 0.96
Research priorities for the development and implementation of serological tools for malaria surveillance. F1000Prime Rep (2014) 0.94
Association of antibodies to Plasmodium falciparum reticulocyte binding protein homolog 5 with protection from clinical malaria. Front Microbiol (2014) 0.93
Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. PLoS One (2014) 0.92
Recent advances in recombinant protein-based malaria vaccines. Vaccine (2015) 0.91
Humanized HLA-DR4.RagKO.IL2RγcKO.NOD (DRAG) mice sustain the complex vertebrate life cycle of Plasmodium falciparum malaria. Malar J (2014) 0.87
The influence of host genetics on erythrocytes and malaria infection: is there therapeutic potential? Malar J (2015) 0.83
Geographically weighted regression of land cover determinants of Plasmodium falciparum transmission in the Ashanti Region of Ghana. Int J Health Geogr (2014) 0.83
Analysis of Erythrocyte Invasion Mechanisms of Plasmodium falciparum Clinical Isolates Across 3 Malaria-Endemic Areas in Ghana. J Infect Dis (2015) 0.82
Subclass responses and their half-lives for antibodies against EBA175 and PfRh2 in naturally acquired immunity against Plasmodium falciparum malaria. Malar J (2014) 0.82
Progress and prospects for blood-stage malaria vaccines. Expert Rev Vaccines (2016) 0.82
Malaria Vaccines: Moving Forward After Encouraging First Steps. Curr Trop Med Rep (2015) 0.82
Genetic Resistance to Malaria Is Associated With Greater Enhancement of Immunoglobulin (Ig)M Than IgG Responses to a Broad Array of Plasmodium falciparum Antigens. Open Forum Infect Dis (2015) 0.82
Co-infection of long-term carriers of Plasmodium falciparum with Schistosoma haematobium enhances protection from febrile malaria: a prospective cohort study in Mali. PLoS Negl Trop Dis (2014) 0.81
Malaria vaccine clinical trials: what's on the horizon. Curr Opin Immunol (2015) 0.80
Time-to-infection by Plasmodium falciparum is largely determined by random factors. BMC Med (2015) 0.79
Differing rates of antibody acquisition to merozoite antigens in malaria: implications for immunity and surveillance. J Leukoc Biol (2016) 0.78
Transcriptomic evidence for modulation of host inflammatory responses during febrile Plasmodium falciparum malaria. Sci Rep (2016) 0.77
Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system. Sci Rep (2016) 0.77
Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design. Hum Vaccin Immunother (2015) 0.76
The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria. Sci Rep (2016) 0.75
Implications from predicted B-cell and T-cell epitopes of Plasmodium falciparum merozoite proteins EBA175-RII and Rh5. Bioinformation (2016) 0.75
Binding of Plasmodium falciparum Merozoite Surface Proteins DBLMSP and DBLMSP2 to Human Immunoglobulin M Is Conserved among Broadly Diverged Sequence Variants. J Biol Chem (2016) 0.75
Comparison of allele frequencies of Plasmodium falciparum merozoite antigens in malaria infections sampled in different years in a Kenyan population. Malar J (2016) 0.75
Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection. Front Microbiol (2016) 0.75
Comparative Antibody Responses Against three Antimalarial Vaccine Candidate Antigens from Urban and Rural Exposed Individuals in Gabon. Eur J Microbiol Immunol (Bp) (2016) 0.75
Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal 'C-tag'. Int J Parasitol (2017) 0.75
A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection. NPJ Vaccines (2017) 0.75
Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet (2012) 17.62
Gamma-globulin and acquired immunity to human malaria. Nature (1961) 13.07
Pyrethroid resistance in African anopheline mosquitoes: what are the implications for malaria control? Trends Parasitol (2010) 8.80
Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr (2008) 6.08
Invasion of red blood cells by malaria parasites. Cell (2006) 5.94
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis (2002) 4.14
Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol (1993) 3.99
Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature (2011) 3.83
Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun (2005) 3.72
Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun (2008) 3.51
Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine (2004) 3.51
A research agenda for malaria eradication: vaccines. PLoS Med (2011) 3.33
A field trial to assess a blood-stage malaria vaccine. N Engl J Med (2011) 3.20
A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A (2010) 2.90
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One (2009) 2.79
Sickle cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria. J Infect Dis (2008) 2.77
Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Cell Host Microbe (2008) 2.66
Large-scale screening for novel low-affinity extracellular protein interactions. Genome Res (2008) 2.62
The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med (2010) 2.61
Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun (2009) 2.22
Reticulocyte-binding protein homologue 5 - an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Int J Parasitol (2008) 2.19
Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol (2009) 2.17
The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun (2011) 2.11
Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis (2011) 1.98
Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J Clin Invest (2008) 1.96
Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med (2009) 1.95
Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. Infect Immun (2006) 1.87
Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis (2010) 1.79
An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum infection. Clin Infect Dis (2013) 1.72
Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design. Proc Natl Acad Sci U S A (2008) 1.69
Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol (2013) 1.68
Sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-1 (MSP-1) of Plasmodium falciparum. Gene (2003) 1.63
Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol (2009) 1.46
Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens. PLoS Pathog (2012) 1.43
An EGF-like protein forms a complex with PfRh5 and is required for invasion of human erythrocytes by Plasmodium falciparum. PLoS Pathog (2011) 1.42
A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants. Vaccine (2012) 1.39
Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. J Immunol (2008) 1.34
Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol (1994) 1.23
Whole parasite vaccination approaches for prevention of malaria infection. Trends Immunol (2012) 1.18
In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized. Infect Immun (2007) 1.15
New emerging Plasmodium falciparum genotypes in children during the transition phase from asymptomatic parasitemia to malaria. Am J Trop Med Hyg (2002) 1.10
Clinical manifestations of new versus recrudescent malaria infections following anti-malarial drug treatment. Malar J (2012) 1.03
Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans. J Infect Dis (2013) 1.01
Adjusting for heterogeneity of malaria transmission in longitudinal studies. J Infect Dis (2011) 0.94
The pathogenic basis of malaria. Nature (2002) 10.44
A research agenda to underpin malaria eradication. PLoS Med (2011) 5.34
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
Mind bomb is a ubiquitin ligase that is essential for efficient activation of Notch signaling by Delta. Dev Cell (2003) 4.30
In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun (2002) 4.02
Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature (2011) 3.83
Impact of National Clinical Guideline recommendations for revascularization of persistently occluded infarct-related arteries on clinical practice in the United States. Arch Intern Med (2011) 3.73
Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun (2005) 3.72
A field trial to assess a blood-stage malaria vaccine. N Engl J Med (2011) 3.20
Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun (2002) 3.08
X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med (2007) 2.94
A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A (2010) 2.90
Plasmodium biology: genomic gleanings. Cell (2003) 2.89
Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine (2007) 2.88
Sickle cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria. J Infect Dis (2008) 2.77
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One (2008) 2.70
Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Cell Host Microbe (2008) 2.66
Large-scale screening for novel low-affinity extracellular protein interactions. Genome Res (2008) 2.62
Season, fever prevalence and pyrogenic threshold for malaria disease definition in an endemic area of Mali. Trop Med Int Health (2005) 2.57
Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol (2011) 2.54
Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J (2008) 2.49
Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. J Infect Dis (2013) 2.47
Risk factors for malaria infection and anemia for pregnant women in the Sahel area of Bandiagara, Mali. Acta Trop (2003) 2.47
CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol (2002) 2.45
Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J Immunol (2009) 2.43
False-negative rapid diagnostic tests for malaria and deletion of the histidine-rich repeat region of the hrp2 gene. Am J Trop Med Hyg (2012) 2.43
Parasite ligand-host receptor interactions during invasion of erythrocytes by Plasmodium merozoites. Int J Parasitol (2004) 2.37
Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg (2003) 2.29
Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med (2008) 2.24
Identification of multiple chondroitin sulfate A (CSA)-binding domains in the var2CSA gene transcribed in CSA-binding parasites. J Infect Dis (2005) 2.24
Ethical data release in genome-wide association studies in developing countries. PLoS Med (2009) 2.23
Differential var gene transcription in Plasmodium falciparum isolates from patients with cerebral malaria compared to hyperparasitaemia. Mol Biochem Parasitol (2006) 2.22
A randomized trial of doxycycline for Mansonella perstans infection. N Engl J Med (2009) 2.21
Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine (2005) 2.21
Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. J Infect Dis (2004) 2.20
Space-time clustering of childhood malaria at the household level: a dynamic cohort in a Mali village. BMC Public Health (2006) 2.20
Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin. Proc Natl Acad Sci U S A (2008) 2.19
Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria. Nature (2005) 2.17
Valid consent for genomic epidemiology in developing countries. PLoS Med (2007) 2.14
Fgf10 regulates hepatopancreatic ductal system patterning and differentiation. Nat Genet (2007) 2.14
A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine (2009) 2.12
Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis (2011) 2.12
The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun (2011) 2.11
Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci U S A (2007) 2.07
Parasite burden and severity of malaria in Tanzanian children. N Engl J Med (2014) 2.07
The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog (2010) 2.03
Advances and challenges in malaria vaccine development. J Clin Invest (2010) 2.03
Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun (2006) 2.02